Haoting Zhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Haoting Zhan has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Yongzhe Li
Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
9 shared publications Haolong Li
Department of Clinical Laboratory, State key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
8 shared publicationsYongmei Liu
Department of Clinical Laboratory, State key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
7 shared publicationsLinlin Cheng
Department of Clinical Laboratory, State key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
5 shared publications- Erhei Dai
The Fifth Hospital of Shijiazhuang
3 shared publications Songxin Yan
Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
3 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (21) , 3578
Multidimensional Tracing of Error Sources and Structured Corrective Strategies for Leukocyte Count and Differential on Automated Hematology Analyzers
Leukocyte count and differential are core indicators for clinical infection assessment, hematological disease diagnosis, and therapeutic monitoring. Currently, clinical testing heavily relies on automated hematology analyzers. Influenced by factors such as specimen characteristics, limited analyzer recognition capability, and improper manual operations, automated testing often produces unreliable results, interfering with clinical decision-making and threatening patient safety. Existing studies remain fragmented, lacking a multidimensional error-tracing framework and practical corrective strategies covering the entire testing workflow. A narrative review was conducted to summarize the causes, identification methods, and corrective strategies for unreliable leukocyte results. Relevant literature up to August 2026 was searched in PubMed/MEDLINE and CNKI. We categorized multidimensional error sources into specimen-related interferents, leukocyte morphological and developmental abnormalities, and preanalytical or systematic factors, and established a practical diagnostic workflow spanning from anomaly recognition to result reporting. By incorporating both legacy and current analytical systems, we compared the characteristic scattergram patterns of various interferents across analyzers with different detection principles, broadening the applicability to diverse clinical laboratories. To better ensure the reliability of corrective strategies and provide diverse alternative options, we not only summarized widely accepted routine practices but also included case-based experimental methods. The proposed multidimensional error-tracing system and practical diagnostic workflow significantly improve analytical accuracy and reduce clinical risks. However, current hematology analyzers cannot automatically identify or correct complex interferences. Future systems must integrate multi-platform advantages, optimize complex cell recognition capabilities, and enrich multidimensional scattergram information to overcome existing analytical limitations. Furthermore, integrating artificial intelligence technology holds immense potential to drive automated hematology analysis toward a more intelligent and precise direction.
- 29 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (21) , 3578
Open AccessMultidimensional Tracing of Error Sources and Structured Corrective Strategies for Leukocyte Count and Differential on Automated Hematology Analyzers
Leukocyte count and differential are core indicators for clinical infection assessment, hematological disease diagnosis, and therapeutic monitoring. Currently, clinical testing heavily relies on automated hematology analyzers. Influenced by factors such as specimen characteristics, limited analyzer recognition capability, and improper manual operations, automated testing often produces unreliable results, interfering with clinical decision-making and threatening patient safety. Existing studies remain fragmented, lacking a multidimensional error-tracing framework and practical corrective strategies covering the entire testing workflow. A narrative review was conducted to summarize the causes, identification methods, and corrective strategies for unreliable leukocyte results. Relevant literature up to August 2026 was searched in PubMed/MEDLINE and CNKI. We categorized multidimensional error sources into specimen-related interferents, leukocyte morphological and developmental abnormalities, and preanalytical or systematic factors, and established a practical diagnostic workflow spanning from anomaly recognition to result reporting. By incorporating both legacy and current analytical systems, we compared the characteristic scattergram patterns of various interferents across analyzers with different detection principles, broadening the applicability to diverse clinical laboratories. To better ensure the reliability of corrective strategies and provide diverse alternative options, we not only summarized widely accepted routine practices but also included case-based experimental methods. The proposed multidimensional error-tracing system and practical diagnostic workflow significantly improve analytical accuracy and reduce clinical risks. However, current hematology analyzers cannot automatically identify or correct complex interferences. Future systems must integrate multi-platform advantages, optimize complex cell recognition capabilities, and enrich multidimensional scattergram information to overcome existing analytical limitations. Furthermore, integrating artificial intelligence technology holds immense potential to drive automated hematology analysis toward a more intelligent and precise direction.
- Open Access
- 6 July 2026
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 40 (18) , e70285
Optimization of Reflex Testing Rules on the Sysmex XN ‐9100 Automated Hematology Line Improves Efficiency and Reduces Repeat Testing in Different Work Areas
Introduction: With the widespread implementation of automated hematology systems, Reflex testing plays a critical role in result verification. However, overly sensitive Reflex rules may lead to excessive repeat testing, increasing workload and prolonging sample turnaround time. This study optimized Reflex rules to improve workflow efficiency while maintaining analytical safety and accuracy. Methods: A retrospective analysis was performed on 78,364 CBC results generated by the Sysmex XN‐9100 hematology automation line in June 2025, including 43,758 outpatient and 34,606 emergency/ward samples. Reflex rules involving LW, PLT‐F, WPC, and RET channels were optimized by differentiating initial and follow‐up visit samples, introducing a 7‐day historical result fluctuation safety range, and simplifying IP message combinations. Middleware simulation compared total Reflex rates and special‐channel repeat counts before and after optimization. Existing autoverification logic, critical alert rules, manual review workflow, and high‐risk disease‐related repeat testing rules were retained. Results: After optimization, total Reflex rates decreased significantly in both work areas ( p < 0.01), from 16.03% to 14.36% in the outpatient area (relative reduction, 10.43%) and from 24.38% to 15.00% in the emergency/ward area (relative reduction, 38.47%). In the emergency/ward area, PLT‐F, WPC, and RET repeat counts decreased by 44.86%, 49.19%, and 61.89%, respectively. Conclusion: XN automation line Reflex rule optimization reduced unnecessary repeat testing through initial/follow‐up visit differentiation and historical fluctuation thresholds while retaining core risk‐interception rules, supporting improved hematology workflow efficiency and reduced reagent consumption.
- 6 July 2026
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 40 (18) , e70285
Open AccessOptimization of Reflex Testing Rules on the Sysmex XN ‐9100 Automated Hematology Line Improves Efficiency and Reduces Repeat Testing in Different Work Areas
Introduction: With the widespread implementation of automated hematology systems, Reflex testing plays a critical role in result verification. However, overly sensitive Reflex rules may lead to excessive repeat testing, increasing workload and prolonging sample turnaround time. This study optimized Reflex rules to improve workflow efficiency while maintaining analytical safety and accuracy. Methods: A retrospective analysis was performed on 78,364 CBC results generated by the Sysmex XN‐9100 hematology automation line in June 2025, including 43,758 outpatient and 34,606 emergency/ward samples. Reflex rules involving LW, PLT‐F, WPC, and RET channels were optimized by differentiating initial and follow‐up visit samples, introducing a 7‐day historical result fluctuation safety range, and simplifying IP message combinations. Middleware simulation compared total Reflex rates and special‐channel repeat counts before and after optimization. Existing autoverification logic, critical alert rules, manual review workflow, and high‐risk disease‐related repeat testing rules were retained. Results: After optimization, total Reflex rates decreased significantly in both work areas ( p < 0.01), from 16.03% to 14.36% in the outpatient area (relative reduction, 10.43%) and from 24.38% to 15.00% in the emergency/ward area (relative reduction, 38.47%). In the emergency/ward area, PLT‐F, WPC, and RET repeat counts decreased by 44.86%, 49.19%, and 61.89%, respectively. Conclusion: XN automation line Reflex rule optimization reduced unnecessary repeat testing through initial/follow‐up visit differentiation and historical fluctuation thresholds while retaining core risk‐interception rules, supporting improved hematology workflow efficiency and reduced reagent consumption.
- 31 January 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 44 (3) , 1279-1291
Evaluation of inflammatory-thrombosis panel as a diagnostic tool for vascular Behçet’s disease
Objectives Vascular Behçet’s disease (VBD) is prevalent in 40% of BD, but lacks laboratory biomarker for timely diagnosis. We aimed to establish a diagnostic panel for discerning VBD and non-VBD patients and identify hemostatic-thrombotic markers most related to VBD pathogenesis using machine learning algorithm. Objectives A total of 338 BD patients comprising 123 VBD and 215 non-VBD were enrolled. Twenty-six clinical and laboratory features selected from LassoCV were included in multiple classifier to choose the optimal model for VBD differentiation. The Shapley Additive exPlanations (SHAP) was employed to interpret the contribution of model features for VBD prediction. Logistic regression analysis and nomogram were conducted to screen risk factors of VBD. Results Inflammatory (neutrophils%, NK cells, IL-6), hematological (hemoglobin, hemoglobin distribution width (HDW)) and thrombosis (activated partial thromboplastin clotting time (APTT), D-dimer) parameters were elevated in VBD. Then we chose top contributors from XGBoost model and performed ten-fold cross validation, the diagnostic accuracy of which exceeded 0.90. Utilizing SHAP method, we identified higher incidence of arterial thrombosis or aneurysm and deep vein thrombosis, upregulated NK cell count, HDW, APTT and D-dimer, downregulated reticulocyte%, B cell count, red blood cell distribution width, cellular hemoglobin (CH) and TNF-α would ultimately generate the phenotype of VBD. Severity, hemoglobin, mean corpuscular hemoglobin, CH, HDW, APTT and D-dimer were found as potential risk factors for vascular outcomes among BD. Results Our study developed a well-performed model leveraging clinical and laboratory parameters for differentiating VBD. Inflammatory and thrombotic risk factors are potential contributors to VBD. Key Points • Inflammatory (neutrophils%, NK cells, IL-6), hematological (HGB, HDW) and thrombosis (APTT, D-dimer) parameters were elevated in VBD. • We firstly developed an inflammatory-thrombosis model as a diagnostic tool for VBD. • HGB, MCH, CH, HDW, APTT and D-dimer are potential risk factors for VBD.
- 31 January 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 44 (3) , 1279-1291
Evaluation of inflammatory-thrombosis panel as a diagnostic tool for vascular Behçet’s disease
Objectives Vascular Behçet’s disease (VBD) is prevalent in 40% of BD, but lacks laboratory biomarker for timely diagnosis. We aimed to establish a diagnostic panel for discerning VBD and non-VBD patients and identify hemostatic-thrombotic markers most related to VBD pathogenesis using machine learning algorithm. Objectives A total of 338 BD patients comprising 123 VBD and 215 non-VBD were enrolled. Twenty-six clinical and laboratory features selected from LassoCV were included in multiple classifier to choose the optimal model for VBD differentiation. The Shapley Additive exPlanations (SHAP) was employed to interpret the contribution of model features for VBD prediction. Logistic regression analysis and nomogram were conducted to screen risk factors of VBD. Results Inflammatory (neutrophils%, NK cells, IL-6), hematological (hemoglobin, hemoglobin distribution width (HDW)) and thrombosis (activated partial thromboplastin clotting time (APTT), D-dimer) parameters were elevated in VBD. Then we chose top contributors from XGBoost model and performed ten-fold cross validation, the diagnostic accuracy of which exceeded 0.90. Utilizing SHAP method, we identified higher incidence of arterial thrombosis or aneurysm and deep vein thrombosis, upregulated NK cell count, HDW, APTT and D-dimer, downregulated reticulocyte%, B cell count, red blood cell distribution width, cellular hemoglobin (CH) and TNF-α would ultimately generate the phenotype of VBD. Severity, hemoglobin, mean corpuscular hemoglobin, CH, HDW, APTT and D-dimer were found as potential risk factors for vascular outcomes among BD. Results Our study developed a well-performed model leveraging clinical and laboratory parameters for differentiating VBD. Inflammatory and thrombotic risk factors are potential contributors to VBD. Key Points • Inflammatory (neutrophils%, NK cells, IL-6), hematological (HGB, HDW) and thrombosis (APTT, D-dimer) parameters were elevated in VBD. • We firstly developed an inflammatory-thrombosis model as a diagnostic tool for VBD. • HGB, MCH, CH, HDW, APTT and D-dimer are potential risk factors for VBD.
- Top Cited PapersOpen Access
- 7 January 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 219 (1)
Neuro-Behçet’s disease: an update of clinical diagnosis, biomarkers, and immunopathogenesis
Neuro-Behçet’s disease (NBD) is a more severe but rare symptom of Behçet’s disease, which is mainly divided into parenchymal NBD (p-NBD) involving brain stem, spinal cord, and cerebral cortex. Non-p-NBD manifests as intracranial aneurysm, cerebral venous thrombosis, peripheral nervous system injuries, and mixed parenchymal and non-parenchymal disease. p-NBD is pathologically characterized by perivasculitis presenting with cerebrospinal fluid (CSF) pleocytosis, elevated total protein, and central nervous system (CNS) infiltration of macrophages and neutrophils, which are subdivided into acute and chronic progressive stages according to relapsing–remitting courses and responses to steroids. The diagnosis of NBD depends heavily on clinical features and magnetic resonance imaging (MRI) findings. The lack of laboratory biomarkers has hindered standard diagnostics. CSF interleukin (IL)-6 is the most investigated dimension of NBD and correlates with NBD activity, therapeutic responses, and prognosis. Further investigations have focused on inflammatory biomarkers that reflect the activation of innate and adaptive immune responses. Higher levels of CSF migration inhibitory factor and immunosuppressive acidic protein indicated the activation of macrophages in the CNS; increased IL-17, IL-10, T-bet/GATA-3, and retinoic acid related orphan receptor (ROR)-γt/Foxp3 ratios, marking the disrupted scale of the Th1/Th2 and Th17/Treg axis; and elevated B-cell activating factor of the TNF family (BAFF) and IgA/IgM intrathecal synthesis, suggesting that B cells play a dominant role in NBD. CNS destruction and degeneration as a consequence of neuroinflammatory cascades were confirmed by elevated CSF levels of NFL, β2MG, and MBP. Autoantibodies, including anti-STIP-1, anti-Mtch1, anti-B-Crystallin, and anti-m-Hsp65, provide substantial evidence for autoimmune essence and underlying microbiological infections in NBD immunopathogenesis. We summarized opinions on the clinical diagnosis, biomarkers, and pathological findings of NBD.
- 7 January 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 219 (1)
Top Cited PapersOpen AccessNeuro-Behçet’s disease: an update of clinical diagnosis, biomarkers, and immunopathogenesis
Neuro-Behçet’s disease (NBD) is a more severe but rare symptom of Behçet’s disease, which is mainly divided into parenchymal NBD (p-NBD) involving brain stem, spinal cord, and cerebral cortex. Non-p-NBD manifests as intracranial aneurysm, cerebral venous thrombosis, peripheral nervous system injuries, and mixed parenchymal and non-parenchymal disease. p-NBD is pathologically characterized by perivasculitis presenting with cerebrospinal fluid (CSF) pleocytosis, elevated total protein, and central nervous system (CNS) infiltration of macrophages and neutrophils, which are subdivided into acute and chronic progressive stages according to relapsing–remitting courses and responses to steroids. The diagnosis of NBD depends heavily on clinical features and magnetic resonance imaging (MRI) findings. The lack of laboratory biomarkers has hindered standard diagnostics. CSF interleukin (IL)-6 is the most investigated dimension of NBD and correlates with NBD activity, therapeutic responses, and prognosis. Further investigations have focused on inflammatory biomarkers that reflect the activation of innate and adaptive immune responses. Higher levels of CSF migration inhibitory factor and immunosuppressive acidic protein indicated the activation of macrophages in the CNS; increased IL-17, IL-10, T-bet/GATA-3, and retinoic acid related orphan receptor (ROR)-γt/Foxp3 ratios, marking the disrupted scale of the Th1/Th2 and Th17/Treg axis; and elevated B-cell activating factor of the TNF family (BAFF) and IgA/IgM intrathecal synthesis, suggesting that B cells play a dominant role in NBD. CNS destruction and degeneration as a consequence of neuroinflammatory cascades were confirmed by elevated CSF levels of NFL, β2MG, and MBP. Autoantibodies, including anti-STIP-1, anti-Mtch1, anti-B-Crystallin, and anti-m-Hsp65, provide substantial evidence for autoimmune essence and underlying microbiological infections in NBD immunopathogenesis. We summarized opinions on the clinical diagnosis, biomarkers, and pathological findings of NBD.
- 21 April 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 559, 119681
Significance of immunoglobulins synthesis with central nervous system involvement in Neuro-Behçet’s disease
- 21 April 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 559, 119681
Significance of immunoglobulins synthesis with central nervous system involvement in Neuro-Behçet’s disease
- 12 February 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (2) , e29446
Omicron BA.4/5 neutralization and cell‐mediated immune responses in relation to baseline immune status and breakthrough infection among PLWH: A follow‐up cohort study
There is a paucity of data on hybrid immunity (vaccination plus breakthrough infection [BI]), especially cell‐mediated responses to Omicron among immunosuppressed patients. We aim to investigate humoral and cellular responses to Omicron BA.4/5 among people living with HIV (PLWH) with/without BIs, the most prevalent variant of concern after the reopening of China. Based on our previous study, we enrolled 77 PLWH with baseline immune status of severe acute respiratory syndrome coronavirus 2 specific antibodies after inactivated vaccination. “Correlates of protection,” including serological immunoassays, T cell phenotypes and memory B cells (MBC) were determined in PLWH without and with BI, together with 16 PLWH with reinfections. Higher inhibition rate of neutralizing antibodies (NAb) against BA.4/5 was elicited among PLWH with BI than those without. Omicron‐reactive IL4 + CD8 + T cells were significantly elevated in PLWH experienced postvaccine infection contrasting with those did not. NAb towards wild type at baseline was associated with prolonged negative conversion time for PLWH whereas intermediate MBCs serve as protecting effectors. We uncovered that hybrid immunity intensified more protection on BA.4/5 than vaccination did. Strengthened surveillance on immunological parameters and timely clinical intervention on PLWH deficient in protection would reduce the severity and mortality in the context of coexistence with new Omicron subvariants.
- 12 February 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (2) , e29446
Omicron BA.4/5 neutralization and cell‐mediated immune responses in relation to baseline immune status and breakthrough infection among PLWH: A follow‐up cohort study
There is a paucity of data on hybrid immunity (vaccination plus breakthrough infection [BI]), especially cell‐mediated responses to Omicron among immunosuppressed patients. We aim to investigate humoral and cellular responses to Omicron BA.4/5 among people living with HIV (PLWH) with/without BIs, the most prevalent variant of concern after the reopening of China. Based on our previous study, we enrolled 77 PLWH with baseline immune status of severe acute respiratory syndrome coronavirus 2 specific antibodies after inactivated vaccination. “Correlates of protection,” including serological immunoassays, T cell phenotypes and memory B cells (MBC) were determined in PLWH without and with BI, together with 16 PLWH with reinfections. Higher inhibition rate of neutralizing antibodies (NAb) against BA.4/5 was elicited among PLWH with BI than those without. Omicron‐reactive IL4 + CD8 + T cells were significantly elevated in PLWH experienced postvaccine infection contrasting with those did not. NAb towards wild type at baseline was associated with prolonged negative conversion time for PLWH whereas intermediate MBCs serve as protecting effectors. We uncovered that hybrid immunity intensified more protection on BA.4/5 than vaccination did. Strengthened surveillance on immunological parameters and timely clinical intervention on PLWH deficient in protection would reduce the severity and mortality in the context of coexistence with new Omicron subvariants.
- Open Access
SARS-CoV-2 Vaccine Uptake among Patients with Chronic Liver Disease: A Cross-Sectional Analysis in Hebei Province, China
Chronic liver disease (CLD) patients have higher mortality and hospitalization rates after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to explore SARS-CoV-2 vaccine perceptions, side effects, factors associated with nonvaccination and attitudes toward fourth-dose vaccine among CLD patients. The differences between vaccinated and unvaccinated groups among 1491 CLD patients and the risk factors associated with nonvaccination status were analyzed. In total, 1239 CLD patients were immunized against SARS-CoV-2. CLD patients have a high level of trust in the government and clinicians and were likely to follow their recommendations for vaccination. Reasons reported for nonvaccination were mainly concerns about the vaccines affecting their ongoing treatments and the fear of adverse events. However, only 4.84% of patients reported mild side effects. Risk factors influencing nonvaccination included being older in age, having cirrhosis, receiving treatments, having no knowledge of SARS-CoV-2 vaccine considerations and not receiving doctors’ positive advice on vaccination. Furthermore, 20.6% of completely vaccinated participants refused the fourth dose because they were concerned about side effects and believed that the complete vaccine was sufficiently protective. Our study proved that SARS-CoV-2 vaccines were safe for CLD patients. Our findings suggest that governments and health workers should provide more SARS-CoV-2 vaccination information and customize strategies to improve vaccination coverage and enhance vaccine protection among the CLD population.
Open AccessSARS-CoV-2 Vaccine Uptake among Patients with Chronic Liver Disease: A Cross-Sectional Analysis in Hebei Province, China
Chronic liver disease (CLD) patients have higher mortality and hospitalization rates after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to explore SARS-CoV-2 vaccine perceptions, side effects, factors associated with nonvaccination and attitudes toward fourth-dose vaccine among CLD patients. The differences between vaccinated and unvaccinated groups among 1491 CLD patients and the risk factors associated with nonvaccination status were analyzed. In total, 1239 CLD patients were immunized against SARS-CoV-2. CLD patients have a high level of trust in the government and clinicians and were likely to follow their recommendations for vaccination. Reasons reported for nonvaccination were mainly concerns about the vaccines affecting their ongoing treatments and the fear of adverse events. However, only 4.84% of patients reported mild side effects. Risk factors influencing nonvaccination included being older in age, having cirrhosis, receiving treatments, having no knowledge of SARS-CoV-2 vaccine considerations and not receiving doctors’ positive advice on vaccination. Furthermore, 20.6% of completely vaccinated participants refused the fourth dose because they were concerned about side effects and believed that the complete vaccine was sufficiently protective. Our study proved that SARS-CoV-2 vaccines were safe for CLD patients. Our findings suggest that governments and health workers should provide more SARS-CoV-2 vaccination information and customize strategies to improve vaccination coverage and enhance vaccine protection among the CLD population.
- 21 June 2023
- Published by Springer Nature in Immunologic Research
- Vol. 71 (6) , 860-872
Integrated analyses delineate distinctive immunological pathways and diagnostic signatures for Behcet’s disease by leveraging gene microarray data
Behcet’s disease (BD) is a chronic inflammatory vasculitis and clinically heterogeneous disorder caused by immunocyte aberrations. Comprehensive research on gene expression patterns in BD illuminating its aetiology is lacking. E-MTAB-2713 downloaded from ArrayExpress was analysed to screen differentially expressed genes (DEGs) using limma. Random forest (RF) and neural network (NN) classification models composed of gene signatures were established using the E-MTAB-2713 training set and subsequently verified using GSE17114. Single sample gene set enrichment analysis was used to assess immunocyte infiltration. After identifying DEGs in E-MTAB-2713, pathogen-triggered, lymphocyte-mediated and angiogenesis- and glycosylation-related inflammatory pathways were discovered to be predominant in BD episodes. Gene signatures from the RF and NN diagnostic models, together with genes enriched in angiogenesis and glycosylation pathways, well discriminated the clinical subtypes of BD manifesting as mucocutaneous, ocular and large vein thrombosis involvement in GSE17114. Moreover, a distinctive immunocyte profile revealed T, NK and dendritic cell activation in BD compared to the findings in healthy controls. Our findings suggested that EPHX1, PKP2, EIF4B and HORMAD1 expression in CD14+ monocytes and CSTF3 and TCEANC2 expression in CD16+ neutrophils could serve as combined gene signatures for BD phenotype differentiation. Pathway genes comprising ATP2B4, MYOF and NRP1 for angiogenesis and GXYLT1, ENG, CD69, GAA, SIGLEC7, SIGLEC9 and SIGLEC16 for glycosylation also might be applicable diagnostic markers for subtype identification.
- 21 June 2023
- Published by Springer Nature in Immunologic Research
- Vol. 71 (6) , 860-872
Integrated analyses delineate distinctive immunological pathways and diagnostic signatures for Behcet’s disease by leveraging gene microarray data
Behcet’s disease (BD) is a chronic inflammatory vasculitis and clinically heterogeneous disorder caused by immunocyte aberrations. Comprehensive research on gene expression patterns in BD illuminating its aetiology is lacking. E-MTAB-2713 downloaded from ArrayExpress was analysed to screen differentially expressed genes (DEGs) using limma. Random forest (RF) and neural network (NN) classification models composed of gene signatures were established using the E-MTAB-2713 training set and subsequently verified using GSE17114. Single sample gene set enrichment analysis was used to assess immunocyte infiltration. After identifying DEGs in E-MTAB-2713, pathogen-triggered, lymphocyte-mediated and angiogenesis- and glycosylation-related inflammatory pathways were discovered to be predominant in BD episodes. Gene signatures from the RF and NN diagnostic models, together with genes enriched in angiogenesis and glycosylation pathways, well discriminated the clinical subtypes of BD manifesting as mucocutaneous, ocular and large vein thrombosis involvement in GSE17114. Moreover, a distinctive immunocyte profile revealed T, NK and dendritic cell activation in BD compared to the findings in healthy controls. Our findings suggested that EPHX1, PKP2, EIF4B and HORMAD1 expression in CD14+ monocytes and CSTF3 and TCEANC2 expression in CD16+ neutrophils could serve as combined gene signatures for BD phenotype differentiation. Pathway genes comprising ATP2B4, MYOF and NRP1 for angiogenesis and GXYLT1, ENG, CD69, GAA, SIGLEC7, SIGLEC9 and SIGLEC16 for glycosylation also might be applicable diagnostic markers for subtype identification.
- 22 January 2023
- Published by Elsevier in Journal of Infection
- Vol. 86 (5) , e138-e141
Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis
- 22 January 2023
- Published by Elsevier in Journal of Infection
- Vol. 86 (5) , e138-e141
Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis
- 3 January 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (1) , e28428
Booster shot of inactivated SARS‐CoV‐2 vaccine induces potent immune responses in people living with HIV
This study aimed to investigate the immunogenicity to SARS‐CoV‐2 and evasive subvariants BA.4/5 in people living with HIV (PLWH) following a third booster shot of inactivated SARS‐CoV‐2 vaccine. We conducted a cross‐sectional study in 318 PLWH and 241 healthy controls (HC) using SARS‐CoV‐2 immunoassays. Vaccine‐induced immunological responses were compared before and after the third dose. Serum levels of IgG anti‐RBD and inhibition rate of NAb were significantly elevated at the “post‐third dose” sampling time compared with the pre‐third dose in PLWH, but were relatively decreased in contrast with those of HCs. Induced humoral and cellular responses attenuated over time after triple‐dose vaccination. The neutralizing capacity against BA.4/5 was also intensified but remained below the positive inhibition threshold. Seropositivity of SARS‐CoV‐2‐specific antibodies in PLWH was prominently lower than that in HC. We also identified age, CD4 cell counts, time after the last vaccination, and WHO staging type of PLWH as independent factors associated with the seropositivity of antibodies. PLWH receiving booster shot of inactivated vaccines generate higher antibody responses than the second dose, but lower than that in HCs. Decreased anti‐BA.4/5 responses than that of WT impede the protective effect of the third dose on Omicron prevalence.
- 3 January 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (1) , e28428
Booster shot of inactivated SARS‐CoV‐2 vaccine induces potent immune responses in people living with HIV
This study aimed to investigate the immunogenicity to SARS‐CoV‐2 and evasive subvariants BA.4/5 in people living with HIV (PLWH) following a third booster shot of inactivated SARS‐CoV‐2 vaccine. We conducted a cross‐sectional study in 318 PLWH and 241 healthy controls (HC) using SARS‐CoV‐2 immunoassays. Vaccine‐induced immunological responses were compared before and after the third dose. Serum levels of IgG anti‐RBD and inhibition rate of NAb were significantly elevated at the “post‐third dose” sampling time compared with the pre‐third dose in PLWH, but were relatively decreased in contrast with those of HCs. Induced humoral and cellular responses attenuated over time after triple‐dose vaccination. The neutralizing capacity against BA.4/5 was also intensified but remained below the positive inhibition threshold. Seropositivity of SARS‐CoV‐2‐specific antibodies in PLWH was prominently lower than that in HC. We also identified age, CD4 cell counts, time after the last vaccination, and WHO staging type of PLWH as independent factors associated with the seropositivity of antibodies. PLWH receiving booster shot of inactivated vaccines generate higher antibody responses than the second dose, but lower than that in HCs. Decreased anti‐BA.4/5 responses than that of WT impede the protective effect of the third dose on Omicron prevalence.